SC
GBT

Sarissa Consulting’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Sarissa Consulting’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1.77M Buy
+26,000
New +$1.43M 1.83% 22

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sarissa Consulting's GBT Position: Q3 2022 in Review

Sarissa Consulting opened a new position in Global Blood Therapeutics, Inc. (GBT) in Q3 2022: 26,000 shares worth $1.77M. The stake represents 1.83% of the portfolio and ranks #22 among its holdings.

247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

  • Sarissa Consulting held 26,000 shares of Global Blood Therapeutics, Inc. worth $1.77M as of Q3 2022.
  • Global Blood Therapeutics, Inc. was a new Sarissa Consulting position in Q3 2022.
  • Global Blood Therapeutics, Inc. made up 1.83% of Sarissa Consulting's portfolio in Q3 2022, its #22 holding.
  • 247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Sarissa Consulting's 13F filing for Q3 2022, filed 14 Nov 2022.